Lokelma approved in the EU for the treatment of adults with hyperkalaemia

AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.

• Source: Worldpharmanews
• 586
• March 27, 2018